Keywords
Kidney diseases
Complications
How to Cite
Abstract
Introduction: Sodium-glucose cotransporter-2 inhibitors (SGLT2i), such as Empagliflozin, Dapagliflozin, and Canagliflozin, are indicated for the treatment of diabetes and chronic kidney disease (CKD). However, there are complications associated with this therapy, making it important to clarify them to ensure treatment safety and efficacy. This study aimed to evaluate the complications of SGLT2i in patients with kidney disease through an integrative literature review. Methodology: The PubMed, SciELO, and BVS databases were used, applying the Health Sciences Descriptors (DeCS) and Medical Subject Headings (MeSH) with the following search strategy: (SGLT2 inhibitors) AND (kidney diseases) AND (complications). The inclusion criteria were: full-text articles, studies from the last five years, published in Portuguese or English, systematic reviews, clinical trials, meta-analyses, literature reviews, and post hoc analyses. A total of 136 articles were identified, but only 17 studies met the inclusion criteria. Results: Adverse effects associated with SGLT2i use in patients with kidney disease were observed, including an increased risk of fungal, urinary tract, and genital infections, ketoacidosis, volume depletion, decreased estimated glomerular filtration rate, renal function decline, and acute kidney injury. Conclusion: The therapeutic benefits of SGLT2i use in patients with kidney disease outweigh the risks, considering their protective effect against renal function decline and adverse cardiovascular events. However, further studies are needed to better understand the adverse effects.
References
AGARWAL, R.; ANKER, S.; FILIPPATOS, G. et al. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant, jun. 2022. DOI: 10.1093/ndt/gfab336. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34850173/. Acesso em: 20 jan. 2025.
CHUANG, M. H.; TANG, Y. S.; CHEN, J. Y. et al. Abrupt decline in estimated glomerular filtration rate after initiating sodium-glucose cotransporter 2 inhibitors predicts clinical outcomes: uma revisão sistemática e meta-análise. Diabetes & Metabolism Journal, v. 48, n. 2, p. 242-252, mar. 2024. DOI: 10.4093/dmj.2023.0201. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10995480/. Acesso em: 21 jan. 2025.
ESCOTT, G. M.; DA SILVEIRA, L. G.; CANCELIER, V. D. A. et al. Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease. Journal of Diabetes and Complications, v. 35, n. 2, p. 107774, fev. 2021. DOI: 10.1016/j.jdiacomp.2020.107774. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33168397/. Acesso em: 21 jan. 2025.
GE, S.; LIU, R.; MAO, Y. et al. Safety of SGLT2 inhibitors in three chronic diseases. Int Heart J., 2023. DOI: 10.1536/ihj.22-441. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37005318/. Acesso em: 20 jan. 2025.
GONZÁLEZ, DE; FORESTO, RD; RIBEIRO, AB. Inibidores do SGLT-2 no diabetes: foco na renoproteção. Revista da Associação Médica Brasileira (1992), São Paulo, v. 1, p. s17-s24, 13 jan. 2020. DOI: 10.1590/1806-9282.66.S1.17. Disponível em: https://www.revistas.usp.br/ramb. Acesso em: 21 jan. 2025.
HEERSPINK, H.; CHERNEY, D.; POSTMUNS, D. et al. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int., jan. 2022. DOI: 10.1016/j.kint.2021.09.005. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34560136/. Acesso em: 20 jan. 2025.
HSIA, D. S.; GROVE, O.; CEFALU, W. T. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Current Opinion in Endocrinology & Diabetes and Obesity, v. 24, n. 1, p. 1, nov. 2016.
KALLURI, S. R.; BHUTTA, T. H.; HANNOODEE, H. et al. Do SGLT2 inhibitors improve cardio-renal outcomes in patients with type II diabetes mellitus: uma revisão sistemática. Cureus, v. 13, n. 9, p. e17668, 2 set. 2021. DOI: 10.7759/cureus.17668. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489544/. Acesso em: 21 jan. 2025.
KAZE, A.; ZHUO, M.; KIM, S. et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol., 23 mar. 2022. DOI: 10.1186/s12933-022-01476-x. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35321742/. Acesso em: 20 jan. 2025.
KAZE, A. D.; WHEELER, D.; MCMURRAY, J. J. et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: uma meta-análise. Cardiovascular Diabetology, v. 21, n. 1, 23 mar. 2022.
KALANTAR-ZADEH, K. et al. Chronic kidney disease. The Lancet, v. 398, n. 10302, p. 786–802, 24 jun. 2021.
LEVIN, A.; PERKOVIC, V.; WHEELER, D. et al. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial. Clin J Am Soc Nephrol., 2020. DOI: 10.2215/CJN.14901219. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32994159/. Acesso em: 20 jan. 2025.
LIU, Y.; AN, C.; LIU, P. et al. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: uma revisão sistemática e meta-análise. Ren Fail., v. 45, n. 1, 29 maio 2023.
MENDES, K. D. S.; SILVEIRA, R. C. DE C. P.; GALVÃO, C. M. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto Enfermagem, v. 17, n. 4, p. 758–764, 2008.
OSHIMA, M.; NEUEN, B.; LI, J. et al. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial. J Am Soc Nephrol., 2020. DOI: 10.1681/ASN.2020050723. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32998938/. Acesso em: 20 jan. 2025.
OSHIMA, M.; JARDINE, M. J.; AGARWAL, R. et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International, v. 99, n. 4, p. 999-1009, abr. 2021. DOI: 10.1016/j.kint.2020.10.042. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33316282/. Acesso em: 21 jan. 2025.
SALAH, H. M.; AL'AREF, S. J.; KHAN, M. S. et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. American Heart Journal, v. 232, p. 10-22, fev. 2021. DOI: 10.1016/j.ahj.2020.10.064. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33214130/. Acesso em: 21 jan. 2025.
SOCIEDADE BRASILEIRA DE DIABETES. Avaliação e Tratamento da Doença Renal do Diabetes. Disponível em: https://diretriz.diabetes.org.br/avaliacao-e-tratamento-da-doenca-renal-do-diabetes/. Acesso em: 13 jan. 2025.
TSAI, W. C.; HSU, S. P.; CHIU, Y. L. et al. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, Londres, v. 12, n. 10, p. e060655, 2022. DOI: 10.1136/bmjopen-2021-060655. Disponível em: https://bmjopen.bmj.com/content/12/10/e060655. Acesso em: 21 jan. 2025.
WANNER, C.; ILIEV, H.; DUARTE, N. et al. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in Therapy, v. 41, n. 7, p. 2826-2844, jul. 2024. DOI: 10.1007/s12325-024-02879-w. Disponível em: https://doi.org/10.1007/s12325-024-02879-w. Acesso em: 21 jan. 2025.
WHEELER, D.; JONGS, N.; STEFÁNSSON, B. et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International, v. 100, n. 1, p. 215–224, jul. 2021.
WHALEN, Karen; FINKELL, Richard; PANAVELIL, Thomas A. Farmacologia ilustrada. 6. ed. Porto Alegre: ArtMed, 2016. E-book. p. 346. ISBN 9788582713235. Disponível em: https://app.minhabiblioteca.com.br/reader/books/9788582713235/. Acesso em: 13 jan. 2025.
WHEELER, D. C.; TOTO, R.; STEFÁNSSON, B. et al. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol Dial Transplant, 2022. DOI: 10.1093/ndt/gfab335. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34850160/. Acesso em: 20 jan. 2025.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Amanda Safira Araújo Mendes, Amanda Medeiros Pinheiro Borges, Amanda Magdah Pereira de Azevedo Dantas, Ana Cecília Leão de Carvalho, Ana Zélia Carrilho Câmara, Eduardo George Medeiros Araújo das Chagas, Laura Géssica Dantas da Silva Rocha, Lucas Diniz Carneiro Leão, Manoela Cacho de Santana, Rodrigo Dantas do Nascimento Filho, Sofia Bezerra Rocha, Vinicius Melo Brito, Deborah de Melo Magalhães Padilha
